Cargando…

Interleukin 35-Producing Exosomes Suppress Neuroinflammation and Autoimmune Uveitis

Corticosteroids are effective therapy for autoimmune diseases but serious adverse effects preclude their prolonged use. However, immune-suppressive biologics that inhibit lymphoid proliferation are now in use as corticosteroid sparing-agents but with variable success; thus, the need to develop alter...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Minkyung, Choi, Jin Kyeong, Jittayasothorn, Yingyos, Egwuagu, Charles E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272665/
https://www.ncbi.nlm.nih.gov/pubmed/32547555
http://dx.doi.org/10.3389/fimmu.2020.01051
_version_ 1783542303437094912
author Kang, Minkyung
Choi, Jin Kyeong
Jittayasothorn, Yingyos
Egwuagu, Charles E.
author_facet Kang, Minkyung
Choi, Jin Kyeong
Jittayasothorn, Yingyos
Egwuagu, Charles E.
author_sort Kang, Minkyung
collection PubMed
description Corticosteroids are effective therapy for autoimmune diseases but serious adverse effects preclude their prolonged use. However, immune-suppressive biologics that inhibit lymphoid proliferation are now in use as corticosteroid sparing-agents but with variable success; thus, the need to develop alternative immune-suppressive approaches including cell-based therapies. Efficacy of ex-vivo-generated IL-35-producing regulatory B-cells (i35-Bregs) in suppressing/ameliorating encephalomyelitis or uveitis in mouse models of multiple sclerosis or uveitis, respectively, is therefore a promising therapeutic approach for CNS autoimmune diseases. However, i35-Breg therapy in human uveitis would require producing autologous Bregs from each patient to avoid immune-rejection. Because exosomes exhibit minimal toxicity and immunogenicity, we investigated whether i35-Bregs release exosomes that can be exploited therapeutically. Here, we demonstrate that i35-Bregs release exosomes that contain IL-35 (i35-Exosomes). In this proof-of-concept study, we induced experimental autoimmune uveitis (EAU), monitored EAU progression by fundoscopy, histology, optical coherence tomography and electroretinography, and investigated whether i35-Exosomes treatment would suppress uveitis. Mice treated with i35-Exosomes developed mild EAU with low EAU scores and disease protection correlated with expansion of IL-10 and IL-35 secreting Treg cells with concomitant suppression of Th17 responses. In contrast, significant increase of Th17 cells in vitreous and retina of control mouse eyes was accompanied by severe choroiditis, massive retinal-folds, and photoreceptor cell damage. These hallmark features of severe uveitis were absent in exosome-treated mice and visual impairment detected by ERG was modest compared to control mice. Absence of toxicity or alloreactivity associated with exosomes thus makes i35-Exosomes attractive therapeutic option for delivering IL-35 into CNS tissues.
format Online
Article
Text
id pubmed-7272665
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72726652020-06-15 Interleukin 35-Producing Exosomes Suppress Neuroinflammation and Autoimmune Uveitis Kang, Minkyung Choi, Jin Kyeong Jittayasothorn, Yingyos Egwuagu, Charles E. Front Immunol Immunology Corticosteroids are effective therapy for autoimmune diseases but serious adverse effects preclude their prolonged use. However, immune-suppressive biologics that inhibit lymphoid proliferation are now in use as corticosteroid sparing-agents but with variable success; thus, the need to develop alternative immune-suppressive approaches including cell-based therapies. Efficacy of ex-vivo-generated IL-35-producing regulatory B-cells (i35-Bregs) in suppressing/ameliorating encephalomyelitis or uveitis in mouse models of multiple sclerosis or uveitis, respectively, is therefore a promising therapeutic approach for CNS autoimmune diseases. However, i35-Breg therapy in human uveitis would require producing autologous Bregs from each patient to avoid immune-rejection. Because exosomes exhibit minimal toxicity and immunogenicity, we investigated whether i35-Bregs release exosomes that can be exploited therapeutically. Here, we demonstrate that i35-Bregs release exosomes that contain IL-35 (i35-Exosomes). In this proof-of-concept study, we induced experimental autoimmune uveitis (EAU), monitored EAU progression by fundoscopy, histology, optical coherence tomography and electroretinography, and investigated whether i35-Exosomes treatment would suppress uveitis. Mice treated with i35-Exosomes developed mild EAU with low EAU scores and disease protection correlated with expansion of IL-10 and IL-35 secreting Treg cells with concomitant suppression of Th17 responses. In contrast, significant increase of Th17 cells in vitreous and retina of control mouse eyes was accompanied by severe choroiditis, massive retinal-folds, and photoreceptor cell damage. These hallmark features of severe uveitis were absent in exosome-treated mice and visual impairment detected by ERG was modest compared to control mice. Absence of toxicity or alloreactivity associated with exosomes thus makes i35-Exosomes attractive therapeutic option for delivering IL-35 into CNS tissues. Frontiers Media S.A. 2020-05-29 /pmc/articles/PMC7272665/ /pubmed/32547555 http://dx.doi.org/10.3389/fimmu.2020.01051 Text en Copyright © 2020 Kang, Choi, Jittayasothorn and Egwuagu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Kang, Minkyung
Choi, Jin Kyeong
Jittayasothorn, Yingyos
Egwuagu, Charles E.
Interleukin 35-Producing Exosomes Suppress Neuroinflammation and Autoimmune Uveitis
title Interleukin 35-Producing Exosomes Suppress Neuroinflammation and Autoimmune Uveitis
title_full Interleukin 35-Producing Exosomes Suppress Neuroinflammation and Autoimmune Uveitis
title_fullStr Interleukin 35-Producing Exosomes Suppress Neuroinflammation and Autoimmune Uveitis
title_full_unstemmed Interleukin 35-Producing Exosomes Suppress Neuroinflammation and Autoimmune Uveitis
title_short Interleukin 35-Producing Exosomes Suppress Neuroinflammation and Autoimmune Uveitis
title_sort interleukin 35-producing exosomes suppress neuroinflammation and autoimmune uveitis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272665/
https://www.ncbi.nlm.nih.gov/pubmed/32547555
http://dx.doi.org/10.3389/fimmu.2020.01051
work_keys_str_mv AT kangminkyung interleukin35producingexosomessuppressneuroinflammationandautoimmuneuveitis
AT choijinkyeong interleukin35producingexosomessuppressneuroinflammationandautoimmuneuveitis
AT jittayasothornyingyos interleukin35producingexosomessuppressneuroinflammationandautoimmuneuveitis
AT egwuagucharlese interleukin35producingexosomessuppressneuroinflammationandautoimmuneuveitis